Intervention

sipuleucel-T

ClinicalTrials.gov intervention label

Explore related research

Search across original and mapped records

Search results distinguish clinical terminology from original registry names. Shared trial participation does not imply treatment or approval.

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 15 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials15
Recruiting0
Common conditions23
Lead sponsors shown5
Advertisement

Clinical trials

15 shown
Open- Label Trial of Sipuleucel-T Administered to Active Surveillance Patients for Newly Diagnosed Prostate CancerNCT03686683 · 2018-10-18
COMPLETED
A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate CancerNCT01981122 · 2013-09-01
COMPLETED
Sipuleucel-T With or Without Radiation Therapy in Treating Patients With Hormone-Resistant Metastatic Prostate CancerNCT01807065 · 2013-06-25
COMPLETED
Provenge With or Without pTVG-HP DNA Booster Vaccine in Prostate CancerNCT01706458 · 2013-05-20
COMPLETED
Sipuleucel-T and Ipilimumab for Advanced Prostate CancerNCT01832870 · 2013-04-01
COMPLETED
Sipuleucel-T Manufacturing Demonstration StudyNCT01477749 · 2012-06-01
COMPLETED
Concurrent vs. Sequential Sipuleucel-T & Abiraterone Treatment in Men With Metastatic Castrate Resistant Prostate CancerNCT01487863 · 2011-12-01
COMPLETED
Sipuleucel-T in Metastatic Castrate Resistant Prostate CancerNCT01338012 · 2011-12-01
TERMINATED
Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate CancerNCT01431391 · 2011-09-01
COMPLETED
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate CancerNCT01306890 · 2011-01-27
COMPLETED
Open Label Study of Sipuleucel-T in Metastatic Prostate CancerNCT00901342 · 2009-10-01
COMPLETED
To Evaluate Sipuleucel-T Manufactured With Different Concentrations of (PA2024) AntigenNCT00715078 · 2008-10-01
COMPLETED
APC8015 and Bevacizumab in Treating Patients With Prostate CancerNCT00027599 · 2001-12-01
COMPLETED
Immunotherapy With APC8015 (Sipuleucel-T, Provenge) for Asymptomatic, Metastatic, Hormone-Refractory Prostate CancerNCT01133704 · 2000-05-01
COMPLETED
Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone TherapyNCT00005947 · 1999-11-01
COMPLETED

Common conditions

Prostate Cancer9Adenocarcinoma of the Prostate2Advanced Prostate Cancer1Bone Metastases1Cancer of Prostate1Cancer of the Prostate1Castrate Resistant Prostate Cancer1Castration-resistant Prostate Cancer1Hormone Refractory Prostate Cancer1Hormone-Refractory Prostate Cancer1Hormone-resistant Prostate Cancer1Metastatic Prostate Cancer1Neoplasms, Prostate1Neoplasms, Prostatic1Prostate Cancer Metastatic1Prostate Neoplasms1Prostatic Adenocarcinoma1Prostatic Cancer1Prostatic Neoplasm1Prostatic Neoplasms1Recurrent Prostate Cancer1Soft Tissue Metastases1Stage IV Prostate Cancer1

Trial status mix

COMPLETED14
TERMINATED1

Phase mix

PHASE210
PHASE33
PHASE11
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.